全文获取类型
收费全文 | 72598篇 |
免费 | 5596篇 |
国内免费 | 3992篇 |
专业分类
耳鼻咽喉 | 438篇 |
儿科学 | 1311篇 |
妇产科学 | 532篇 |
基础医学 | 5145篇 |
口腔科学 | 1596篇 |
临床医学 | 8810篇 |
内科学 | 17022篇 |
皮肤病学 | 1283篇 |
神经病学 | 1841篇 |
特种医学 | 4266篇 |
外科学 | 10156篇 |
综合类 | 10885篇 |
现状与发展 | 10篇 |
一般理论 | 4篇 |
预防医学 | 6862篇 |
眼科学 | 927篇 |
药学 | 5386篇 |
38篇 | |
中国医学 | 2908篇 |
肿瘤学 | 2766篇 |
出版年
2024年 | 161篇 |
2023年 | 1225篇 |
2022年 | 2738篇 |
2021年 | 3208篇 |
2020年 | 2947篇 |
2019年 | 2330篇 |
2018年 | 2279篇 |
2017年 | 2122篇 |
2016年 | 2585篇 |
2015年 | 2561篇 |
2014年 | 4977篇 |
2013年 | 4777篇 |
2012年 | 4554篇 |
2011年 | 4793篇 |
2010年 | 4161篇 |
2009年 | 4087篇 |
2008年 | 4051篇 |
2007年 | 3994篇 |
2006年 | 3642篇 |
2005年 | 3134篇 |
2004年 | 2322篇 |
2003年 | 2073篇 |
2002年 | 1808篇 |
2001年 | 1667篇 |
2000年 | 1369篇 |
1999年 | 1066篇 |
1998年 | 995篇 |
1997年 | 855篇 |
1996年 | 666篇 |
1995年 | 713篇 |
1994年 | 646篇 |
1993年 | 446篇 |
1992年 | 445篇 |
1991年 | 372篇 |
1990年 | 304篇 |
1989年 | 304篇 |
1988年 | 279篇 |
1987年 | 227篇 |
1986年 | 191篇 |
1985年 | 180篇 |
1984年 | 131篇 |
1983年 | 79篇 |
1982年 | 101篇 |
1981年 | 89篇 |
1980年 | 73篇 |
1979年 | 74篇 |
1978年 | 71篇 |
1977年 | 62篇 |
1976年 | 58篇 |
1974年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
41.
42.
John Lennon Silva Cunha Amanda Almeida Leite Thamiris de Castro Abrantes Lorena Passoni Vervloet Thayn Melo de Lima Morais Gerson de Oliveira Paiva Neto Tatiana Nayara Librio Kimura Snia Maria Soares Ferreira Ricardo Luiz Cavalcanti de Albuquerque‐Júnior Aline Corrêa Abraho Mario Jos Romaach Bruno Augusto Benevenuto de Andrade Oslei Paes de Almeida Ciro Dantas Soares 《Journal of cutaneous pathology》2021,48(1):24-33
43.
44.
You-Wen Tan 《World Journal of Meta-Analysis》2021,9(6):488-495
Nilotinib is a specific breakpoint cluster region-Abelson leukemia virus-tyrosine kinase inhibitor that is used as an effective first- or second-line treatment in imatinib-resistant chronic myelogenous leukemia (CML) patients. Hepatotoxicity due to nilotinib is a commonly reported side effect; however, abnormal liver function test (LFT) results have been reported in asymptomatic cases. When alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels are more than five-fold the upper limit of the normal (ULN) or when the serum total bilirubin level is more than three-fold the ULN, dose modification or discontinuation of nilotinib is recommended, resulting in decreased levels of hematological indicators in certain patients with CML. Nilotinib-induced hyperbilirubinemia typically manifests as indirect bilirubinemia without elevated ALT or AST levels. Such abnormal liver functioning is thus not attributed to the presence of a true histologic lesion of the liver. The underlying mechanism may be related to the inhibition of uridine diphosphate glucuronosyltransferase activity. Therefore, nilotinib dose adjustment is not recommended for this type of hyperbilirubinemia, and in the absence of elevated liver enzyme levels or presence of abnormal LFT findings, physicians should consider maintaining nilotinib dose intensity without modifications. 相似文献
45.
Jennifer Wang Jonathan G. Stine Scott L. Cornella Curtis K. Argo Steven M. Cohn 《临床与转化肝病杂志(英文版)》2015,3(4):254-259
Background and Aims: Gastric antral vascular ectasia (GAVE) is commonly found in patients with cirrhosis, but it is also associated with other diseases in the absence of cirrhosis. Whether GAVE confers a different severity of gastrointestinal (GI) bleeding between patients with and without cirrhosis remains unknown. We aim to examine whether there is a difference in clinically significant GI bleeding due to GAVE in patients with or without cirrhosis. Methods: This is a retrospective case-control study of patients who were diagnosed with GAVE between January 2000 and June 2014. Patients were categorized into cirrhosis and noncirrhosis groups, and those with an additional GI bleeding source were excluded. Univariate comparisons and multivariable models were constructed using logistic regression. Results: In total, 110 patients diagnosed with GAVE on esophagogastroduodenoscopy (EGD) were included in our analysis; 84 patients had cirrhosis (76.4%) and 26 (23.6%) did not. Active GI bleeding was more prevalent in patients without cirrhosis (63.4% vs. 32.1%, p=0.003) despite similar indications for EGD, and endoscopic treatment with argon plasma coagulation (APC) was required more often in this group, approaching statistical significance (27% vs. 10.7%, p=0.056). There was no difference in bleeding severity, as evidenced by similar re-bleeding rates, surgery, or death attributed to uncontrolled bleeding. The strongest independent risk factor for GI bleeding was the absence of cirrhosis (odds ratio (OR): 5.151 (95% confidence interval (CI): 1.08-24.48, p=0.039). Conclusions: Patients with GAVE in the absence of cirrhosis are at higher risk for active GI bleeding and require more frequent endoscopic treatment than similar patients with cirrhosis. It may be worthwhile to treat GAVE in this population even in the absence of active bleeding. 相似文献
46.
Salaam Semaan 《Emerging infectious diseases》2016,22(10):1863-1864
47.
48.
Diabetes mellitus(DM) negatively affects the development and progression of chronic liver diseases(CLD) of various etiologies. Concurrent DM and CLD are also associated with worse clinical outcomes with respect to mortality, the occurrence of hepatic decompensation, and the development of hepatocellular carcinoma(HCC). Unfortunately, early diagnosis and optimal treatment of DM can be challenging, due to the lack of established clinical guidelines as well as the medical complexity of this patient population. We conducted an exploratory review of relevant literature to provide an up-to-date review for internists and hepatologists caring for this patient population. We reviewed the epidemiological and pathophysiological associations between DM and CLD, the impact of insulin resistance on the progression and manifestations of CLD, the pathogenesis of hepatogenic diabetes, as well as the practical challenges in diagnosis and monitoring of DM in this patient population. We also reviewed the latest clinical evidence on various pharmacological antihyperglycemic therapies with an emphasis on liver disease-related clinical outcomes. Finally, we proposed an algorithm for managing DM in patients with CLD and discussed the clinical and research questions that remain to be addressed. 相似文献
49.
50.